Fresenius to divest antibody and biotech business
This article was originally published in Scrip
Executive Summary
The Fresenius Group has said it is to discontinue its Fresenius Biotech subsidiary, focusing instead on four other business segments; Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.